Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Promising new preventative treatment option for population of men at high risk of prostate cancer

20.10.2004


Toremifene study finds significant reduction in the incidence of prostate cancer for men with high grade PIN

Toremifene, a drug currently used to treat breast cancer in women, was found to reduce the incidence of prostate cancer for men at high risk for the disease. In a study presented today at the American Association for Cancer Research Third Annual International Conference on Frontiers in Cancer Prevention Research, scientists found that patients at all dose levels for toremifene had a lower cumulative incidence of cancer after 12 months of treatment, with the 20 mg dose contributing the greatest effect.

All participating patients had high-grade prostatic intraepithelial neoplasia or PIN, characterized by abnormal cells in the lining of the prostate ducts. Early research suggests that most patients with high-grade PIN will develop prostate cancer within 10 years, but more research is needed to confirm those findings.



"For men with high-grade PIN, the prospect of developing prostate cancer is a very real possibility," said Dr. Mitchell S. Steiner, chief executive officer with GTx, Inc. "With no effective treatment options available, doctors and patients often feel defenseless against the onset of prostate cancer. "Fortunately, these results offer a promising new preventive approach to prostate cancer treatment. A chemopreventive agent like toremifene is a first step toward the possibility of stopping prostate cancer before it starts and gives patients and doctors a chance to fight this pervasive disease."

In a multi-center, double-blind study, 514 patients with high-grade PIN and no cancer, determined by pre-study biopsies, were randomized to placebo or toremifene 20 mg, 40 mg or 60 mg given orally once a day. Patients were re-biopsied at six and 12 months.

During the study, 24.4 percent of patients taking 20 mg dose of toremifene were diagnosed with prostate cancer versus 31.2 percent of patients taking placebo. Among the patients who completed 12 months of treatment, the reduction in prostate cancer incidence was 48 percent for patients receiving 20 mg of toremifene compared to those in the placebo group.

According to the National Cancer Institute, prostate cancer is the most commonly diagnosed cancer in America among men. With an estimated 220,000 new cases diagnosed each year, one in every five men will get prostate cancer during his lifetime. African-American men are at special risk for the disease. In fact, the incidence rate in African-Americans is 60 percent higher than that in white males and double the mortality rate. An estimated 29,900 American men lose their lives to prostate cancer each year.

Warren Froelich | EurekAlert!
Further information:
http://www.aacr.org

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Regensburg physicists watch electron transfer in a single molecule

For the first time, an international team of scientists based in Regensburg, Germany, has recorded the orbitals of single molecules in different charge states in a novel type of microscopy. The research findings are published under the title “Mapping orbital changes upon electron transfer with tunneling microscopy on insulators” in the prestigious journal “Nature”.

The building blocks of matter surrounding us are atoms and molecules. The properties of that matter, however, are often not set by these building blocks...

Im Focus: University of Konstanz gains new insights into the recent development of the human immune system

Scientists at the University of Konstanz identify fierce competition between the human immune system and bacterial pathogens

Cell biologists from the University of Konstanz shed light on a recent evolutionary process in the human immune system and publish their findings in the...

Im Focus: Transformation through Light

Laser physicists have taken snapshots of carbon molecules C₆₀ showing how they transform in intense infrared light

When carbon molecules C₆₀ are exposed to an intense infrared light, they change their ball-like structure to a more elongated version. This has now been...

Im Focus: Famous “sandpile model” shown to move like a traveling sand dune

Researchers at IST Austria find new property of important physical model. Results published in PNAS

The so-called Abelian sandpile model has been studied by scientists for more than 30 years to better understand a physical phenomenon called self-organized...

Im Focus: Cryo-force spectroscopy reveals the mechanical properties of DNA components

Physicists from the University of Basel have developed a new method to examine the elasticity and binding properties of DNA molecules on a surface at extremely low temperatures. With a combination of cryo-force spectroscopy and computer simulations, they were able to show that DNA molecules behave like a chain of small coil springs. The researchers reported their findings in Nature Communications.

DNA is not only a popular research topic because it contains the blueprint for life – it can also be used to produce tiny components for technical applications.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Global Legal Hackathon at HAW Hamburg

11.02.2019 | Event News

The world of quantum chemistry meets in Heidelberg

30.01.2019 | Event News

Our digital society in 2040

16.01.2019 | Event News

 
Latest News

Gravitational waves will settle cosmic conundrum

15.02.2019 | Physics and Astronomy

Spintronics by 'straintronics'

15.02.2019 | Physics and Astronomy

Platinum nanoparticles for selective treatment of liver cancer cells

15.02.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>